Oramed Pharmaceuticals, Inc. (NASDAQ:ORMP) price target set to $25.00 by HC Wainwright

ME Staff
-
0

Analyst Ratings For Oramed Pharmaceuticals, Inc. (NASDAQ:ORMP)

Today, HC Wainwright set its price target on Oramed Pharmaceuticals, Inc. (NASDAQ:ORMP) to $25.00 per share.

There are 1 Hold Ratings, 1 Buy Ratings, no Strong Buy Ratings, no Sell Ratings on the stock.

The current consensus rating on Oramed Pharmaceuticals, Inc. (NASDAQ:ORMP) is Buy with a consensus target price of $22.50 per share, a potential 458.31% upside.

Some recent analyst ratings include

  • 7/16/2018-Oramed Pharmaceuticals, Inc. (NASDAQ:ORMP) gets downgraded to Neutral by B. Riley


  • On 8/9/2018 Aviad Friedman, Director, bought 2,500 with an average share price of $4.95 per share and the total transaction amounting to $12,375.00.
  • On 7/10/2018 Nadav Kidron, Insider, sold 61 with an average share price of $5.98 per share and the total transaction amounting to $364.78.
  • On 8/2/2017 Xiaopeng Li, Director, bought 89,636 with an average share price of $8.50 per share and the total transaction amounting to $761,906.00.
  • On 4/19/2017 Miriam Kidron, Insider, sold 52,814 with an average share price of $6.33 per share and the total transaction amounting to $334,312.62.
  • On 5/12/2016 Nadav Kidron, CEO, bought 1,000 with an average share price of $6.95 per share and the total transaction amounting to $6,950.00.
  • On 12/30/2015 Miriam Kidron, CTO, sold 50,000 with an average share price of $8.90 per share and the total transaction amounting to $445,000.00.
  • On 12/9/2015 Michael Berelowitz, Director, sold 700 with an average share price of $9.44 per share and the total transaction amounting to $6,608.00.

About Oramed Pharmaceuticals, Inc. (NASDAQ:ORMP)
Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the use of orally ingestible capsules or pills for delivery of polypeptides. Its product portfolio includes ORMD-0801, an oral insulin capsule, which has completed Phase IIb clinical trials for the treatment of diabetes; and ORMD-0901, an analog for GLP-1 gastrointestinal hormone, which has completed Phase Ib clinical trials for the treatment of type 2 diabetes. The company operates primarily in Israel. The company was formerly known as Integrated Security Technologies, Inc. and changed its name to Oramed Pharmaceuticals Inc. in April 2006. Oramed Pharmaceuticals Inc. was founded in 2002 and is based in Jerusalem, Israel.

Recent Trading Activity for Oramed Pharmaceuticals, Inc. (NASDAQ:ORMP)
Shares of Oramed Pharmaceuticals, Inc. closed the previous trading session at 4,01 0,00 0,00 % with shares trading hands.